Argitalpenak (15) Anastasiia Zherniakova argitalpenak

2024

  1. Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19

    Blood Cancer Journal, Vol. 14, Núm. 1

  2. Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma

    Blood Advances

2022

  1. Pericentromeric Non-Coding DNA Transcription Is Associated with Niche Impairment in Patients with Ineffective or Partially Effective Multiple Myeloma Treatment

    International Journal of Molecular Sciences, Vol. 23, Núm. 6

2021

  1. Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies

    Blood Cancer Journal, Vol. 11, Núm. 12

  2. Infectious complications in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation

    Cellular Therapy and Transplantation, Vol. 10, Núm. 1, pp. 63-68

  3. Polymorphism of Interleukins and Tumor Necrosis Factor α Genes in Multiple Myeloma Patients with Autologous Hematopoietic Stem Cell Transplantation

    Klinicheskaya Onkogematologiya/Clinical Oncohematology, Vol. 14, Núm. 3, pp. 340-346

  4. Potential predictors and response quality after autologous hematopoietic stem cell transplantation in multiple myeloma

    Klinicheskaya Onkogematologiya/Clinical Oncohematology, Vol. 14, Núm. 3, pp. 333-339

  5. Retrospective survival analysis of multiple Myeloma patients after autologous hematopoietic stem cell transplantation

    Klinicheskaya Onkogematologiya/Clinical Oncohematology, Vol. 14, Núm. 1, pp. 73-79

2020

  1. Autologous hematopoietic stem cell transplantation in multiple myeloma treatment with and without the use of granulocyte colony-stimulating factor in post-transplantation period

    Klinicheskaya Onkogematologiya/Clinical Oncohematology, Vol. 13, Núm. 3, pp. 289-294

2019

  1. Clinical efficacy of chelation therapy in patients with low-risk myelodysplastic syndrome

    Klinicheskaya Onkogematologiya/Clinical Oncohematology, Vol. 12, Núm. 2, pp. 120-124

  2. Experience with the use of thio/mel conditioning regimen prior to autologous hematopoietic stem cell transplantation in multiple myeloma

    Klinicheskaya Onkogematologiya/Clinical Oncohematology, Vol. 12, Núm. 3, pp. 282-288

  3. Factors associated with efficient harvesting and engraftment of auto-transplants in multiple myeloma patients

    Klinicheskaya Onkogematologiya/Clinical Oncohematology, Vol. 12, Núm. 1, pp. 32-36

  4. Some aspects of autotransplant collection in patients with multiple myeloma

    Voprosy Onkologii, Vol. 65, Núm. 4, pp. 504-509

2018

  1. Hematopoietic stem cell collection in multiple myeloma patients: Influence of the lenalidomide-based therapy and mobilization regimen prior to auto-HSCT

    Klinicheskaya Onkogematologiya/Clinical Oncohematology, Vol. 11, Núm. 2, pp. 192-197

2017

  1. Thrombotic and bleeding risk factors in essential thrombocythemia

    Oncogematologiya, Vol. 12, Núm. 2, pp. 30-38